Skip to main content
Terug
TNGX logo

Tango Therapeutics, Inc.

Datakwaliteit: 100%
TNGX
NASDAQ Healthcare Biotechnology
€ 18,96
▼ € 0,46 (-2,37%)
Marktkapitalisatie: 2,20B
Dagbereik
€ 18,93 € 19,91
52-Weeksbereik
€ 1,03 € 19,91
Volume
2.846.519
50D / 200D Gem.
€ 13,42 / € 8,90
Vorige Slotkoers
€ 19,42

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -21,7 0,4
P/B 6,4 2,9
ROE % -37,2 3,7
Net Margin % -162,9 3,8
Rev Growth 5Y % 13,9 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 13,92% annually over 5 years — strong growth
Debt/Equity of 0,10 — conservative balance sheet
Negative free cash flow of -139,93M
PEG of 0,38 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 34,37%
Capital efficient — spends only 1,68% of revenue on capex

Groei

Revenue Growth (5Y)
13,92%
Revenue (1Y)48,29%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-37,23%
ROIC-21,98%
Net Margin-162,85%
Op. Margin-178,39%

Veiligheid

Debt / Equity
0,10
Current Ratio16,32
Interest Coverage0,00

Waardering

P/E Ratio
-21,68
P/B Ratio6,36
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 48,29% Revenue Growth (3Y) 30,69%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13,92% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 62,38M Net Income (TTM) -101,59M
ROE -37,23% ROA -25,48%
Gross Margin 96,34% Operating Margin -178,39%
Net Margin -162,85% Free Cash Flow (TTM) -139,93M
ROIC -21,98% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,10 Current Ratio 16,32
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -21,68 P/B Ratio 6,36
P/S Ratio 35,31 PEG Ratio 0,38
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,20B Enterprise Value 2,12B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 62,38M 42,07M 36,53M 24,86M 37,04M
Net Income -101,59M -130,30M -101,74M -108,18M -58,24M
EPS (Diluted) -0,87 -1,19 -1,08 -1,23 -0,94
Gross Profit 60,10M 42,07M 36,53M 24,86M 37,04M
Operating Income -111,29M -145,60M -114,17M -111,07M -58,19M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 398,69M 316,49M 402,57M 436,47M 500,16M
Total Liabilities 52,51M 116,98M 149,46M 186,99M 155,41M
Shareholders' Equity 346,18M 199,52M 253,11M 249,48M 344,75M
Total Debt 33,57M 36,49M 38,92M 41,13M 1,50M
Cash & Equivalents 112,28M 69,53M 66,39M 59,97M 142,75M
Current Assets 353,76M 266,34M 346,54M 375,27M 492,34M
Current Liabilities 21,68M 38,17M 45,94M 55,55M 40,69M